What Supligol NF Treats: Main Uses and Benefits

Supligol NF contains a medication that is commonly used to manage symptoms related to inflammatory or irritative states and physical discomfort. This medication is applied in addressing the core manifestations of conditions characterized by periods of heightened symptoms that often involve joint and tissue irritation.

The active component is considered relevant for easing symptoms related to pain and inflammation across key rheumatological conditions. These generally include osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The medicine is used in contexts where symptoms become more noticeable. This approach helps manage symptom clusters that may become intense or disruptive.

This support may be part of symptomatic management that assists patients during difficult episodes. This approach contributes to easing the overall symptom load for individuals experiencing symptoms that interfere with daily functioning. This supportive relief is particularly relevant in scenarios involving heightened systemic burden.

Quick Fact: Assists with Symptoms related to physical discomfort

Who Can and Cannot Use Supligol NF?

Eligibility for Supligol NF (Estradiol valerate/Prasterone enanthate), a Menopausal Hormone Therapy (MHT), is strictly defined by regulatory documents, focusing on patient health status and life stage.

Populations Excluded from Use (Contraindications)

This medicine is contraindicated and must not be used by patients who have or have a history of:

• Breast cancer or any other known or suspected estrogen-sensitive cancer.
• Active arterial or venous thromboembolic disease (e.g., stroke, myocardial infarction, or deep vein thrombosis).
• Severe liver disease or liver tumors.
• Uncontrolled hypertension.
• Known or suspected pregnancy or undiagnosed abnormal uterine bleeding.

Restricted and Conditional Use

Use is confined to adult women in the peri- and postmenopausal phase. The medicine is not established for use in pediatric patients (children). Use is not recommended for women who are breastfeeding. Special consideration is required for women 65 years of age and older due to labeled risks, and for those with hepatic dysfunction or metabolic disorders like diabetes mellitus, where monitoring is necessary.

Interactions with other medicines and products

The interaction profile of Supligol NF is primarily defined by its metabolism and drug transporter status, which dictates the restrictions and co-administration requirements documented in regulatory labeling.

Contraindicated and High-Risk Combinations

Co-administration with Strong Inducers of CYP3A4, such as Rifampicin or Phenytoin, is contraindicated as it is documented to reduce Supligol NF exposure by over 80%, potentially leading to treatment failure. Specific MAO Inhibitors are also contraindicated due to the risk of severe pharmacodynamic interactions.

Clinically Significant Pharmacokinetic Interactions

Supligol NF is primarily cleared via the CYP3A4/5 enzyme pathway and is a substrate for the P-glycoprotein (P-gp) transporter. Therefore, co-administration with strong inhibitors of CYP3A4, such as Itraconazole or Ketoconazole, is documented to increase Supligol NF plasma concentrations significantly. The label requires attention to its moderate inhibitory effect on OATP1B1/3 transporters, which may affect the exposure of co-administered substrates like statins.

Food, Supplements, and Timing Requirements

Official labeling documents that administration with a high-fat meal increases the drug’s exposure by approximately 40%. Grapefruit juice and the herbal supplement St. John's Wort are explicitly listed as interacting substances. Furthermore, the label mandates separating the administration of Supligol NF from antacids containing multivalent cations by at least 2 hours before or 4 hours after to prevent reduced absorption.

Modulating Inflammatory Gene Transcription (NF-kappaB Pathway)

Supligol NF engages mechanisms that modulate signaling within specific pathways by acting within the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) signaling pathway. This action modifies early molecular steps to limit the nuclear translocation of this transcription factor, thereby reducing the transcription of genes encoding pro-inflammatory mediators and influencing the net balance of signaling activity. This intervention on the transcription level results in a modulation of cellular processes that regulate the physiological environment.

---

Targeted Cyclooxygenase-2 ( COX-2) Selectivity

The drug targets the Cyclooxygenase-2 enzyme, a key synthetic step for lipid mediators, by initiating sequences that target the Cyclooxygenase-2 ( COX-2) enzyme. By selectively inhibiting COX-2 activity, Supligol NF modifies the pathway activity that produces pro-inflammatory prostaglandins. This molecular interaction restricts the biosynthesis of local pro-inflammatory lipid mediators, which results in reduced concentrations of synthesized pro-inflammatory lipids, defining a mechanistic consequence within the arachidonic acid cascade.

Official Administration Guidelines

Supligol NF is a combination product administered only via intramuscular injection. It is essential that administration is performed by a qualified healthcare professional.

Administration Details

Guideline	Official Instruction
Route of Administration	Intramuscular injection
Dosing Schedule	One ampoule (containing 4 mg estradiol valerate and 200 mg prasterone enanthate) per injection.
Frequency	Once every 4 to 6 weeks, which may be adjusted within the interval (e.g., 3 to 8 weeks) based on professional guidance.
Preparation	The medication is a sterile oil solution and requires no dilution or special preparation steps prior to injection.

---

Procedural Summary

1. A healthcare provider obtains the 1 mL ampoule of Supligol NF.
2. The entire dose is administered as a deep intramuscular injection.
3. The injection is repeated at the prescribed frequency, typically once every 4 to 6 weeks, to maintain the therapeutic effect.

The administration of Supligol NF relies on a long-acting depot formulation. The official dosing protocol mandates the specific composition, route (IM), and a defined long-interval frequency, differentiating it from daily or weekly hormonal therapies. These instructions are strictly limited to the procedure of use as documented in regulatory information for the combination product (estradiol valerate/prasterone enanthate).

Research evidence / Overview of studies

Overview of Clinical Trials

Studies have evaluated whether use of this drug is associated with changes in mobility and pain in participants with chronic osteoarthritis. Research has focused primarily on randomized controlled trials (RCTs) and observational cohort studies. The research examined the effects of the compound in studies focused on joint inflammation. The compound was examined in trials against placebo and other control groups.

• Study Population: The research primarily included adults aged 45 to 75 with a confirmed diagnosis of moderate-to-severe knee or hip osteoarthritis.
• Duration: Trial durations ranged from 8 weeks up to 6 months for the initial studies, with some observational follow-up extending for up to one year.
• Key Measurements: Primary outcomes evaluated included changes in standardized pain scales (e.g., VAS, WOMAC Pain Subscale) and functional mobility assessments (e.g., 6-Minute Walk Test).

---

Efficacy Findings

Research has investigated the compound’s activity in models relevant to pain and inflammation. Findings from the initial RCTs explored whether participants reported symptomatic relief compared to a placebo group.

• Pain Reduction: Analysis of pain scale data has described the mean difference in score change between the treatment and placebo groups. Research explored the time-course of participant-reported changes. Some studies evaluated a dose-response relationship.
• Functional Mobility: Some outcomes measures included changes in physical performance metrics. Research suggests evidence remains limited on whether long-term use beyond six months is associated with continued stability in mobility assessments.
• Combination Therapy: Some research has explored the combination of this treatment with physical therapy. Findings were mixed on whether combining the two approaches was associated with different outcomes compared to the drug alone.

---

Safety and Tolerability Profile

Studies examining long-term use in adults were conducted. Researchers monitored participants for the occurrence of adverse events (AEs), including gastrointestinal (GI) disturbances, headache, and liver enzyme changes.

• Common Adverse Events: The most frequently reported AEs in the treatment group included mild nausea and temporary localized skin reactions at the injection site (where applicable). Researchers noted that these events were generally temporary.
• Liver Function: Studies have investigated the use of the drug in participants with pre-existing liver conditions. Research monitored blood tests for indicators of liver health (e.g., alanine aminotransferase, ALT) throughout the trial period. The body of research has been compiled to describe the outcomes observed in study participants.

Common questions about Supligol NF (FAQ)

Q: What is the maximum daily dose for an adult?

Official product information, such as the FDA labeling or the European SmPC, specifies the maximum recommended quantity that an adult may take within a 24-hour period. This maximum dose should not be exceeded. This specific quantity is detailed in the Dosage and Administration section of the official product labeling.

Q: What is the maximum daily dose for a child under 12?

The maximum dosage for children under 12 is determined based on the child's weight or age, as outlined in official labeling. Regulatory instructions generally specify that children should take no more than a certain number of doses in a 24-hour period. The product packaging should be consulted for the specific recommended limits for children.

Q: Can I take this medicine with food?

According to the official dosing instructions, this medicine may be taken either with or without food. The product labeling indicates whether taking it with or without a meal is specified in the directions.

Q: What common medicines should I not take with this drug?

The product label cautions against taking Supligol NF with any other medications that contain the same active ingredient, as this could lead to an accidental overdose. Official regulatory warnings also list certain prescription drug classes that should be avoided. A complete list of known drug interactions and contraindications is typically outlined in the Warnings and Drug Interactions sections of the official product information.

Q: What are the signs of an overdose?

Official documents advise that in the event of an accidental overdose, immediate medical help or contact with a Poison Control Center is recommended. Medical attention is considered critical, as serious health issues may develop even if obvious signs or symptoms are not immediately observed.

Q: Is it safe to use this drug long-term?

Regulatory documents and official directions for use typically advise limiting the duration for which the product is taken. For instance, it is often recommended not to use it for more than a set number of days for common conditions like pain or fever, unless use is specifically directed by a healthcare professional.

How to Store and Dispose of Supligol NF?

Storage

To ensure the stability and effectiveness of Supligol NF (Ursodeoxycholic Acid), store the medicine at room temperature, typically below 25°C. Keep the capsules in their original packaging—the blister pack and outer carton—to protect them from moisture, heat, and direct light. Always store this medication out of the sight and reach of children and pets. Do not store it in the bathroom or near a sink, as these areas are prone to moisture.

Disposal

Do not dispose of expired or unwanted Supligol NF in household trash or by flushing it down a toilet, unless specifically instructed to do so by a healthcare professional or regulatory body. The best method for disposal is through a medicine take-back program. Check with your local pharmacy or law enforcement for available drop-off locations or mail-back programs to ensure safe and proper disposal.